↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy of esomeprazole in treating acid-related diseases in Japanese populations

Overview of attention for article published in Clinical and Experimental Gastroenterology, June 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
6 Mendeley
Title
Efficacy of esomeprazole in treating acid-related diseases in Japanese populations
Published in
Clinical and Experimental Gastroenterology, June 2012
DOI 10.2147/ceg.s23926
Pubmed ID
Authors

Mitsushige Sugimoto, Takahisa Furuta

Abstract

Esomeprazole (Nexium(®); AstraZeneca), the S-isomer of omeprazole, is the first proton pump inhibitor (PPI) to be developed as an optical isomer. Compared with omeprazole, esomeprazole has an improved pharmacokinetic profile with regards to CYP2C19 (S-mephenytoin 4'-hydroxylase) genotype, showing increased systemic exposure and less interindividual variability. Further, esomeprazole is a more potent acid inhibitor than other currently available PPIs and is therefore used as a first-line drug for acid-related diseases. While esomeprazole has been available in a number of countries worldwide, the compound only received authorized permission to be marketed in Japan in September 2011. The standard esomeprazole dose in Japan for the treatment of peptic ulcers and gastroesophageal reflux disease (GERD) is 20 mg. Other advised dosages are 10 mg for nonerosive reflux disease and 20 mg twice-daily dosing for eradication of Helicobacter pylori. In Japanese, the effective rate of esomeprazole 20 mg during 24 weeks for GERD patients is 92.0% (88.0%-96.0%), while the prevention of peptic ulcer development using 20 mg for 24 weeks in patients treated with nonsteroidal anti-inflammatory drugs is 96.0% (92.8%-99.1%). Although clinical data are limited, the usefulness of esomeprazole is expected in Japanese subjects given the reduced prevalence of CYP2C19 rapid metabolizers in Japan compared with Western countries.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 33%
Student > Bachelor 2 33%
Unknown 2 33%
Readers by discipline Count As %
Medicine and Dentistry 3 50%
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Unknown 2 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2012.
All research outputs
#3,533,612
of 4,506,935 outputs
Outputs from Clinical and Experimental Gastroenterology
#59
of 82 outputs
Outputs of similar age
#58,531
of 75,175 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#8
of 9 outputs
Altmetric has tracked 4,506,935 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 82 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,175 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.